Compound class:
Synthetic organic
Comment: JSF-3285 is an indazole antibacterial compound discovered using a structure-based approach to optimize DG167 (PubChem CID 70689295), a known inhibitor of Mycobacterium tuberculosis 3-oxoacyl-[acyl-carrier-protein] synthase 1 (also known as β-ketoacyl-ACP synthase, KasA) [2]. JSF-3285 is being investigated as a preclinical candidate for the treatment of tuberculosis (TB). The structure is claimed in patent WO2019046467A1 filed by Rutgers University [1].
|
|
No information available. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
JSF-3285 is an inhibitor of M. tuberculosis KasA which is involved in the biosynthesis of mycolic acid, an essential component of the mycobacterial cell wall [2]. |